Saturday 17 October 2026
Export BFRI’s income statement to Excel — free account
Biofrontera Inc.
BFRI Healthcare Drug Manufacturers Specialty & Generic
Biofrontera Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41.7 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.9%, EPS grew 91.2%, free cash flow grew 45.6% and total debt rose 6.50%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
0.82
0.03
−3.53%
Follow BFRI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.29 | 0.14 | 0.22 | 0.27 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(2.79) | (2.44) | (135.19) | (7.40) | |
P/B ratio |
0.00 | 0.55 | 1.56 | 2.06 | |
Price to Tangible BV |
0.00 | 0.74 | 2.73 | 3.62 | |
EV/Sales |
0.32 | 0.10 | 0.19 | 0.27 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.00) | (0.32) | (0.88) | (1.58) | |
EV/FCF |
(1.00) | (0.32) | (0.87) | (1.58) | |
Quick Ratio |
0.51 | 1.15 | 0.93 | 0.97 | |
Current Ratio |
1.15 | 1.52 | 1.20 | 1.18 | |
Net Debt/EBITDA |
(0.17) | (0.38) | 0.39 | 0.14 | |
Debt/Assets |
28.95% | 16.07% | 19.04% | 19.20% | |
Debt/Equity |
(1.73) | 0.44 | 0.78 | 0.78 | |
Asset Turnover |
2.19 | 1.65 | 2.09 | 2.09 | |
Operating CF/Net income |
0.58 | (0.42) | 0.01 | 2.75 | |
Capex/Depreciation |
0.00 | 0.00 | (0.03) | 0.00 | |
Interest Coverage |
(56.56) | 37.97 | (34.56) | (4.16) | |
Research and Development Expense of Revenue |
12.22% | 4.61% | 8.93% | 3.73% | |
Selling, General and Administrative Expense of Revenue |
148.35% | 51.15% | 109.04% | 80.55% | |
Intangible Assets out of Total Assets |
0.00 | 0.09 | 0.11 | 0.11 | |
Share Based Compensation of Revenue |
3.38% | 1.69% | 3.39% | 2.19% | |
Graham Net Nets |
(0.34) | 0.00 | (0.59) | (0.46) | |
Graham Number |
2.28 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(97.66%) | (180.70%) | (119.75%) | (47.37%) | |
Free Cash Flow Yield |
(112.53%) | (230.48%) | (98.46%) | (64.59%) | |
Revenue per Share |
0.65 | 1.68 | 0.86 | 0.93 | |
Operating CF per Share |
(0.35) | (0.23) | (0.01) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.35) | (0.23) | (0.01) | (0.13) | |
Cash per Share |
0.32 | 0.63 | 0.54 | 0.36 | |
Shareholders Equity per Share |
(0.24) | 1.03 | 0.52 | 0.46 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.24) | 1.03 | 0.52 | 0.46 | |
Free Cash Flow |
(3.82) | (2.37) | (0.07) | (1.66) | |
Working Capital |
1.86 | 6.19 | 2.24 | 1.89 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
(3.58) | 0.00 | (5.56) | (5.67) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.93 | 6.30 | 3.96 | 4.75 | |
Average Payables |
5.70 | 6.93 | 5.45 | 5.15 | |
Average Inventory |
5.43 | 4.04 | 3.88 | 2.56 | |
Average Assets |
16.97 | 25.33 | 20.69 | 22.10 | |
Average Common Equity |
1.47 | 7.46 | 3.27 | 0.64 |
Columns are period end dates